Morbidity and mortality in the antiphospholipid syndrome during a 10-year period: a multicentre prospective study of 1000 patients

Επιστημονική δημοσίευση - Άρθρο Περιοδικού uoadl:3166148 39 Αναγνώσεις

Μονάδα:
Ερευνητικό υλικό ΕΚΠΑ
Τίτλος:
Morbidity and mortality in the antiphospholipid syndrome during a
10-year period: a multicentre prospective study of 1000 patients
Γλώσσες Τεκμηρίου:
Αγγλικά
Περίληψη:
Objectives To assess the prevalence of the main causes of
morbi-mortality in the antiphospholipid syndrome (APS) during a
10-year-follow-up period and to compare the frequency of early
manifestations with those that appeared later.
Methods In 1999, we started an observational study of 1000 APS patients
from 13 European countries. All had medical histories documented when
entered into the study and were followed prospectively during the
ensuing 10years.
Results 53.1% of the patients had primary APS, 36.2% had APS
associated with systemic lupus erythematosus and 10.7% APS associated
with other diseases. Thrombotic events appeared in 166 (16.6%) patients
during the first 5-year period and in 115 (14.4%) during the second
5-year period. The most common events were strokes, transient ischaemic
attacks, deep vein thromboses and pulmonary embolism. 127 (15.5%) women
became pregnant (188 pregnancies) and 72.9% of pregnancies succeeded in
having one or more live births. The most common obstetric complication
was early pregnancy loss (16.5% of the pregnancies). Intrauterine
growth restriction (26.3% of the total live births) and prematurity
(48.2%) were the most frequent fetal morbidities. 93 (9.3%) patients
died and the most frequent causes of death were severe thrombosis
(36.5%) and infections (26.9%). Nine (0.9%) cases of catastrophic APS
occurred and 5 (55.6%) of them died. The survival probability at
10years was 90.7%.
Conclusions Patients with APS still develop significant morbidity and
mortality despite current treatment. It is imperative to increase the
efforts in determining optimal prognostic markers and therapeutic
measures to prevent these complications.
Έτος δημοσίευσης:
2015
Συγγραφείς:
Cervera, R.
Serrano, R.
Pons-Estel, G. J.
Ceberio-Hualde, L.
and Shoenfeld, Y.
de Ramon, E.
Buonaiuto, V.
Jacobsen, S.
and Zeher, M. M.
Tarr, T.
Tincani, A.
Taglietti, M. and
Theodossiades, G.
Nomikou, E.
Galeazzi, M.
Bellisai, F. and
Meroni, P. L.
Derksen, R. H. W. M.
de Groot, P. G. D. and
Baleva, M.
Mosca, M.
Bombardieri, S.
Houssiau, F.
Gris,
J-C
Quere, I.
Hachulla, E.
Vasconcelos, C. and
Fernandez-Nebro, A.
Haro, M.
Amoura, Z.
Miyara, M. and
Tektonidou, M.
Espinosa, G.
Bertolaccini, M. L.
Khamashta,
M. A.
Euro-Phospholipid Project Grp
Περιοδικό:
Annals of the Rheumatic Diseases
Εκδότης:
BMJ Publishing Group
Τόμος:
74
Αριθμός / τεύχος:
6
Σελίδες:
1011-1018
Λέξεις-κλειδιά:
Anticardiolipin Antibodies; Antiphospholipid Antibodies;
Antiphospholipid Syndrome; Autoimmune Diseases; Systemic Lupus
Erythematosus
Επίσημο URL (Εκδότης):
DOI:
10.1136/annrheumdis-2013-204838
Το ψηφιακό υλικό του τεκμηρίου δεν είναι διαθέσιμο.